| Popis: |
Introduction Sex steroid hormones play a key role in bone health, however medical therapies for gender dysphoria lead to hormonal changes. Purpose Understanding the changes in bone mass and body composition is extremely important, because this treatment will be carried out over a long period of time. Methods In a prospective study, we included 19 transgender men (female-to-male transgender persons) before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). Bone densitometry model Hologic-Discovery performed at baseline and after 6, 12 months of therapy. All participants signed the TCLE, project approved by CEP-CAAE: 36823220.6.0000.0062. Results Analysis of 19 transgender men with a mean age of 24 years +/- 10 years. LS-BMD (lumbar spine) at initial time (0m) 1,075±0,238 g/cm2 and after 6 months (6m) 1,044±0,117 g/cm2 and 12 months (12m) after 1,052±0.122 g/cm2, p=0.21; FN-BMD (Femur Neck) 0m= 0.904±0.121 g/cm2; 6m= 0.918±0.108 g/cm2 and 12m= 0.905±0.107 g/cm2; p=0.90. TH-BMD (Total Hip) 0m=1.017±0.139 g/cm2; and 6m= 1.023±0.134 g/cm2; 12m= 1.032±0.136g/cm2; p=0.05. About body composition: the percentage of body fat: 0m=38.8±6.7%, 6m=34.5±7.1%; 12m=34.9±9.0; p=0.09; android/gynecoid ratio: 0.93±0.16, 6m=0.94±0.17; 12m=0.94±0.18 p=0.06, VAT mass (cm3) 431.8±262.1, 6m= 401.8±298.6, 12m= 455.5±322.7 and Lean/Height2 (kg/m2) 0m= 15.52±3.24 6m= 16.15±2.19 kg/ m2; 12m= 15.86±2.22 kg/m2; p Conclusion In 1 year of hormone therapy with testosterone, we did not observe significant differences in bone mass, but in body composition there was a gain in appendicular lean mass. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m., Monday, June 13, 2022 1:00 p.m. - 1:05 p.m. |
